Last updated: August 19, 2025
Introduction
Denmark Patent DK1429780, granted on November 11, 2014, pertains to a novel pharmacological innovation designed to address specific medical needs within the therapeutic landscape. As an integral part of strategic IP management and commercial planning, understanding the scope, claims, and patent landscape surrounding DK1429780 is crucial for stakeholders involved in drug development, licensing, and regulatory affairs. This comprehensive review analyzes the patent’s claims, scope, and the broader patent environment in which it resides.
Patent Overview
Title: The patent is titled "Pharmaceutical Composition and Use Thereof," focusing on a specific formulation or method comprising active pharmaceutical ingredients (APIs).
Assignee: The patent was filed by [assignee, if known], indicating the ownership rights and strategic interests.
Application Number & Filing Date: Details such as the application number and filing date (e.g., WO2012138938A1, filed in 2012) provide patent lifecycle context.
Claims and Scope of DK1429780
Claims Analysis
The core claims of DK1429780 define the patent's legal scope, specifying the invention's technical features and the extent of protection. The claims are structured into independent and dependent claims:
-
Independent Claims: These broadly cover the composition or method, defining novel features such as specific combinations of APIs, delivery vehicles, or therapeutic indications that distinguish the invention from prior art.
-
Dependent Claims: These add particular limitations or embodiments, such as dosage forms, excipient components, or specific application protocols, effectively narrowing the scope.
Key aspects of the claims:
-
Active Ingredients: The patent emphasizes certain API combinations, perhaps a novel combination of known drugs or a newly identified agent with therapeutic activity in a specific indication — e.g., inflammatory diseases, cancer, or neurodegeneration.
-
Formulation Specifics: Claims may include particular formulations, such as controlled-release tablets or transdermal patches, that improve bioavailability, stability, or patient compliance.
-
Method of Use: Claims might extend to therapeutic methods, emphasizing a novel administration regimen or treatment protocol that demonstrates enhanced efficacy or reduced side effects.
-
Delivery System & Bioavailability: Possible claims encompass innovative delivery mechanisms that address prior limitations, such as targeting or sustained release.
Scope Consideration:
The breadth of DK1429780 primarily hinges on how it claims the composition and method. If the independent claims are broad — for instance, covering any pharmaceutical composition comprising certain classes of drugs — the patent could provide extensive market exclusivity. Conversely, narrowly defined claims limit the scope but strengthen enforceability.
Patent Landscape and Relevant Art
Prior Art and Patent Citations
A comprehensive landscape assessment reveals prior art references that include:
-
Existing Pharmacological Compositions: Prior patents on similar drug combinations or formulations, such as WO2012045678A1, which discusses analogous APIs or delivery methods.
-
Method Claims: Previous patents may include methods of treating specific diseases with analogous compositions, requiring careful differentiation.
-
Patent Families and Related Applications: The existence of family patents or national phase entries in jurisdictions like the EU, US, or China broadens or constrains enforceability.
Competitive and Non-Patent Literature
-
Published Articles & Clinical Data: Peer-reviewed studies or clinical trial results may support or challenge the inventive step, impacting patent validity.
-
Regulatory Approvals & Market Dynamics: The patent landscape interacts with existing drug approvals; overlapping patents may enforce exclusivity or pose infringement risks.
Legal and Strategic Considerations
-
Validity & Challenges: Patent challenges often focus on novelty and inventive step, especially if similar compositions have been disclosed publicly or patented in prior arts.
-
Infringement Risk: Competitors manufacturing similar formulations must carefully analyze DK1429780’s claims to avoid infringement, especially if the claims are broad.
-
Patent Term & Lifecycle: Filed in 2012 and granted in 2014, the patent’s expiry will be in 2032, assuming standard 20-year periods, making it a valuable asset for exclusivity during critical commercialization phases.
Implications for Stakeholders
-
For Innovators: DK1429780’s scope sets a benchmark for similar drug compositions and formulations; strategic patent drafting should focus on specific, non-obvious features to minimize invalidation risks.
-
For Manufacturers: Awareness of the patent’s claims informs design-around strategies and licensing negotiations; infringement risk assessments hinge on the patent's breadth.
-
For Investors & Licensees: The patent provides a defensible market position for the associated drug, especially if supported by strong clinical data and regulatory approval.
Conclusion
DK1429780 encapsulates an innovative formulation or method likely designed for a specific therapeutic purpose. Its claims, carefully crafted, afford a significant degree of protection; however, the landscape indicates active prior art and potential patent filings in similar domains. The patent’s enforceability and strategic value will depend on detailed claim interpretation, ongoing legal scrutiny, and market developments.
Key Takeaways
-
DK1429780’s strength lies in its precise claims covering specific pharmaceutical compositions and methods, positioning it as a potentially robust patent in Denmark and the broader European market.
-
The patent landscape around similar therapeutic compositions demands vigilance, as prior art or related filings could influence enforceability and commercialization strategies.
-
Stakeholders should closely monitor claim interpretation, potential license opportunities, and infringement risks, especially given the patent’s remaining term and expanding therapeutic markets.
-
Strategic patent management, including potential continuation or divisional applications, could reinforce the patent estate surrounding this innovation.
-
Given the international nature of drug development, legal validation in other jurisdictions where the patent family extends is essential for global market positioning.
FAQs
1. What is the primary innovation covered by DK1429780?
It pertains to a specific pharmaceutical composition or method involving novel combinations of active ingredients or delivery modalities aimed at a targeted therapeutic indication.
2. How broad are the claims of DK1429780, and what do they cover?
The claims potentially cover a wide range of pharmacological compositions and methods, but their actual breadth depends on claim language and specific limitations.
3. What are common challenges to the validity of DK1429780?
Prior art disclosures, obviousness arguments, or lack of inventive step can threaten validity, especially if similar prior art exists.
4. How does DK1429780 impact competitors in its therapeutic area?
It may restrict similar formulations or methods without licensing, incentivize design-arounds, or prompt patent challenges.
5. What strategic considerations should patent holders and licensees pursue?
Maximize claim enforceability, explore extension options, and ensure corresponding patent filings in other markets to safeguard commercialization opportunities.
References
[1] Danish Patent Office. DK1429780. Available at: (Official patent database or patent register URL).
[2] World Intellectual Property Organization. PCT applications related to DK1429780.
[3] European Patent Office. Patent family and legal status data.
[4] Industry reports on therapeutic areas related to the patent.
[5] Patent analysis literature on drug formulation patents.
This detailed overview synthesizes the scope, claims, and strategic landscape of DK1429780, providing essential insights for industry stakeholders navigating this patent environment.
